These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7517541)

  • 1. Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies.
    Yasuda K; Yamanishi T; Tojo M; Nagashima K; Akimoto S; Shimazaki J
    Prostate; 1994 Jul; 25(1):46-52. PubMed ID: 7517541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
    Takahashi S; Tajima A; Matsushima H; Kawamura T; Tominaga T; Kitamura T
    Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
    Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
    BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
    Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
    Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].
    Kawabe K
    Yakugaku Zasshi; 2006 Mar; 126 Spec no.():199-206. PubMed ID: 16518083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation.
    Gerstenberg T; Blaabjerg J; Nielsen ML; Clausen S
    Invest Urol; 1980 Jul; 18(1):29-31. PubMed ID: 6157651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of an alpha 1-adrenergic blocker (prazosin HCl) on micturition disturbances associated with benign prostatic hypertrophy.
    Shimizu K; Nakai K; Imai K; Yamanaka H
    Urol Int; 1990; 45 Suppl 1():36-9. PubMed ID: 1690479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
    Witjes WP; Rosier FW; de Wildt MJ; van Iersel MP; Debruyne FM; de La Rosette JJ
    J Urol; 1996 Apr; 155(4):1317-23. PubMed ID: 8632523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of tamsulosin hydrochloride on bladder outlet obstruction associated with benign prostatic hyperplasia: effect on urethral pressure profile and cystometrogram].
    Murayama K; Katsumi T; Tajika E; Kawaguchi K; Ueki O
    Hinyokika Kiyo; 1997 Nov; 43(11):799-803. PubMed ID: 9436025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
    [No Abstract]   [Full Text] [Related]  

  • 17. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
    Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
    Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia.
    Eckhardt MD; van Venrooij GE; Boon TA
    Urology; 2001 Dec; 58(6):966-71. PubMed ID: 11744470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
    Ge JP; Gong J; Ma HQ; Wei W; Shang XJ; Zhang ZY; Xu S; Wang D; Gao JP
    Zhonghua Nan Ke Xue; 2008 Oct; 14(10):927-30. PubMed ID: 19157107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.